Literature DB >> 3845321

Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria.

A Nicholson-Weller, D B Spicer, K F Austen.   

Abstract

Erythrocytes from patients with paroxysmal nocturnal hemoglobinuria are deficient in decay-accelerating factor, a membrane protein that inhibits the complement C3 convertases. We studied the expression of this protein on leukocytes and platelets from four patients with paroxysmal nocturnal hemoglobinuria, using cytofluorographic analysis and antibody to decay-accelerating factor. The granulocytes and monocytes had a bimodal distribution of fluorescence, indicating antigen-deficient and antigen-positive subpopulations of cells. In contrast, granulocytes and monocytes from normal donors and patients with other diseases had no antigen-deficient cells. Platelets from the four patients with paroxysmal nocturnal hemoglobinuria had less fluorescence than normal platelets. Furthermore, surface-radiolabeled granulocytes and platelets from one of the four patients, which were maximally deficient in decay-accelerating factor, also lacked antigen that was immunoprecipitable by specific antibody to this protein. Thus, paroxysmal nocturnal hemoglobinuria is a clonal disorder characterized by deficient membrane expression of decay-accelerating factor on granulocytes, monocytes, and platelets, as well as on erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3845321     DOI: 10.1056/NEJM198504253121704

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  37 in total

1.  Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.

Authors:  Fengming Liu; Lin Wu; Gongxiong Wu; Chun Wang; Lining Zhang; Stephen Tomlinson; Xuebin Qin
Journal:  Atherosclerosis       Date:  2014-03-15       Impact factor: 5.162

2.  Retrovirus-induced feline pure red cell aplasia. Hematopoietic progenitors are infected with feline leukemia virus and erythroid burst-forming cells are uniquely sensitive to heterologous complement.

Authors:  J L Abkowitz; R D Holly; C K Grant
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 3.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 4.  [Paroxysmal nocturnal hemoglobinuria].

Authors:  P Blaas; S Weber; G M Hänsch; H H Peter
Journal:  Klin Wochenschr       Date:  1990-03-05

Review 5.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

6.  Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.

Authors:  Jie Lan; Kai Yang; Daniel Byrd; Ningjie Hu; Tohti Amet; Nicole Shepherd; Mona Desai; Jimin Gao; Samir Gupta; Yongtao Sun; Qigui Yu
Journal:  J Immunol       Date:  2014-08-22       Impact factor: 5.422

7.  Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  M H Holguin; L R Fredrick; N J Bernshaw; L A Wilcox; C J Parker
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  DIAGNOSTIC DILEMMAS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.

Authors:  Rajat Kumar; S Dutta; Harsh Kumar; A I Lazar; V K Sashindran
Journal:  Med J Armed Forces India       Date:  2017-06-27

9.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

10.  Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).

Authors:  Gurpanna Saggu; Claudio Cortes; Heather N Emch; Galia Ramirez; Randall G Worth; Viviana P Ferreira
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.